Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement

References

• Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2010:481–488.
   PubMedGoogle Scholar
• Keating MJ, O’Brien S, Albitar M, . Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079–4088.
   PubMed Web of Science ®Google Scholar
• Kay NE, Geyer SM, Call TG, . Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007;109:405–411.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Rai K, Peterson BL, . Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49–53.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, . Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164–1174.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Mayer J, . Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749–1755.
   PubMed Web of Science ®Google Scholar
• Zent CS, Chen JB, Kurten RC, . Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium. Leuk Res 2004;28:495–507.
   PubMed Web of Science ®Google Scholar
• Golay J, Manganini M, Rambaldi A, . Effect of alemtuzumab on neoplastic B cells. Haematologica 2004;89:1476–1483.
   PubMed Web of Science ®Google Scholar
• Zent CS, Secreto CR, Laplant BR, . Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk Res 2008;32:1849–1856.
   PubMed Web of Science ®Google Scholar
• Golay J, Lazzari M, Facchinetti V, . CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001;98:3383–3389.
   PubMed Web of Science ®Google Scholar
• Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol 2008;20:444–449.
   PubMed Web of Science ®Google Scholar
• Glennie MJ, French RR, Cragg MS, . Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007;44:3823–3837.
   PubMed Web of Science ®Google Scholar
• Teeling JL, French RR, Cragg MS, . Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104:1793–1800.
   PubMed Web of Science ®Google Scholar
• Pawluczkowycz AW, Beurskens FJ, Beum PV, . Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol 2009;183:749–758.
   PubMed Web of Science ®Google Scholar
• Clynes R, Towers T, Presta L, . Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443–446.
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, . Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754–758.
   PubMed Web of Science ®Google Scholar
• Bowles JA, Weiner GJ. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods 2005;304:88–99.
   PubMed Web of Science ®Google Scholar
• Golay J, Cortiana C, Manganini M, . The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis. Haematologica 2006;91:322–330.
   PubMed Web of Science ®Google Scholar
• Bleeker WK, Munk ME, Mackus WJ, . Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br J Haematol 2008;140:303–312.
   PubMed Web of Science ®Google Scholar
• Siders WM, Shields J, Garron C, . Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models. Leuk Lymphoma 2010;51:1293–1304.
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Houot R, Goldstein MJ, . CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 2011;117:2423–2432.
   PubMed Web of Science ®Google Scholar
• Lundin J, Osterborg A, Brittinger G, . CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol 1998;16:3257–3563.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Kennedy B, Moreton P, . Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood 2004;103:2027–2031.
   PubMed Web of Science ®Google Scholar
• Zent CS, Call TG, Shanafelt TD, . Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab and rituximab Cancer 2008;113:2110–2118.
   Google Scholar
• Beum PV, Lindorfer MA, Taylor RP. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving. J Immunol 2008;181:2916–2924.
   PubMed Web of Science ®Google Scholar
• Kennedy AD, Beum PV, Solga MD, . Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol 2004;172:3280–3288.
   PubMed Web of Science ®Google Scholar
• Bohana-Kashtan O, Ziporen L, Donin N, . Cell signals transduced by complement. Mol Immunol 2004;41:583–597.
   PubMed Web of Science ®Google Scholar
• Black SM, Schott ME, Batdorf BH, . IL-4 induces protection of vascular endothelial cells against killing by complement and melittin through lipid biosynthesis. Eur J Immunol 2010;40:803–812.
   PubMed Web of Science ®Google Scholar
• Beum PV, Lindorfer MA, Beurskens F, . Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol 2008;181:822–832.
   PubMed Web of Science ®Google Scholar
• Teeling JL, Mackus WJ, Wiegman LJ, . The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177:362–371.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, . Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Morice WG, Kurtin PJ, Hodnefield JM, . Predictive value of blood and bone marrow flow cytometry in B-cell lymphoma classification: comparative analysis of flow cytometry and tissue biopsy in 252 patients. Mayo Clin Proc 2008;83:776–785.
   PubMed Web of Science ®Google Scholar
• Dewald GW, Brockman SR, Paternoster SF, . Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol 2003;121:287–295.
   PubMed Web of Science ®Google Scholar
• Jelinek DF, Tschumper RC, Geyer SM, . Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol 2001;115:854–861.
   PubMed Web of Science ®Google Scholar
• Rassenti LZ, Huynh L, Toy TL, . ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351:893–901.
   PubMed Web of Science ®Google Scholar
• Rossmann ED, Lenkei R, Lundin J, . Performance of calibration standards for antigen quantitation with flow cytometry in chronic lymphocytic leukemia. Cytometry B Clin Cytom 2007;72:450–457.
   PubMed Web of Science ®Google Scholar
• Brando B, Gohde W Jr, Scarpati B, . The “vanishing counting bead” phenomenon: effect on absolute CD34 + cell counting in phosphate-buffered saline-diluted leukapheresis samples. Cytometry 2001;43:154–160.
   PubMedGoogle Scholar
• Edberg JC, Tosic L, Wright EL, . Quantitative analyses of the relationship between C3 consumption, C3b capture, and immune adherence of complement-fixing antibody/DNA immune complexes. J Immunol 1988;141:4258–4265.
   PubMed Web of Science ®Google Scholar
• Harris CL, Lublin DM, Morgan BP. Efficient generation of monoclonal antibodies for specific protein domains using recombinant immunoglobulin fusion proteins: pitfalls and solutions. J Immunol Methods 2002;268:245–258.
   PubMed Web of Science ®Google Scholar
• Macor P, Tedesco F. Complement as effector system in cancer immunotherapy. Immunol Lett 2007;111:6–13.
   PubMed Web of Science ®Google Scholar
• Ricklin D, Hajishengallis G, Yang K, . Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010;11:785–797.
   PubMed Web of Science ®Google Scholar
• Faderl S, Thomas DA, O’Brien S, . Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003;101:3413–3415.
   PubMed Web of Science ®Google Scholar
• Nabhan C, Patton D, Gordon L, . A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma 2004;45:2269–2273.
   PubMed Web of Science ®Google Scholar
• Keating MJ, Flinn I, Jain V, . Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554–3561.
   PubMed Web of Science ®Google Scholar
• Hu W, Ge X, You T, . Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis. Cancer Res 2011;71:2298–2307.
   PubMed Web of Science ®Google Scholar
• Rutkowski MJ, Sughrue ME, Kane AJ, . Cancer and the complement cascade. Mol Cancer Res 2010;8:1453–1465.
   PubMed Web of Science ®Google Scholar
• Allendorf DJ, Yan J, Ross GD, . C5a-mediated leukotriene B4-amplified neutrophil chemotaxis is essential in tumor immunotherapy facilitated by anti-tumor monoclonal antibody and beta-glucan. J Immunol 2005;174:7050–7056.
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A, . Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910–1916.
   PubMed Web of Science ®Google Scholar